| http://purl.uniprot.org/citations/30173083 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/30173083 | http://www.w3.org/2000/01/rdf-schema#comment | "Systemic lupus erythematosus (SLE) is characterized by an autoantibody- and immune complex-mediated inflammatory disease. Since CD5-like (CD5L), also known as apoptosis inhibitor of macrophage (AIM), is as an apoptosis inhibitor that protects the survival of macrophages, T cells, and NKT against proapoptotic agents, which plays an important role in the pathogenesis of various inflammatory diseases, we investigated the possible aberrant production of CD5L and its clinical implications in SLE patients. We measured the serum concentration and ex vivo production of CD5L in 68 SLE patients and 60 sex- and age-matched control individuals using an enzyme-linked immunoabsorbent assay. Serum CD5L concentrations were significantly higher in SLE patients than in healthy control subjects. Increase in CD5L concentration correlated positively and significantly with SLE Disease Activity Index (SLEDAI) score in all SLE patients. Besides, CD5L titers were positively correlated with anti-double stranded DNA antibody (anti-dsDNA) titers, ESR and C-reactive protein (CRP) levels, and negatively correlated with complement 3 (C3) and C4 levels. Serum CD5L concentrations could be significantly decreased after effective treatment of SLE. In addition, the ex vivo release of CD5L upon mitogen activation of peripheral blood mononuclear cells was significantly higher in the SLE groups than in the healthy control group. The above results suggest that the up-regulated production of CD5L is important in the immunopathogenesis of SLE, and may serve as a potential disease marker for the monitoring of SLE disease severity and therapeutic efficacy."xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.intimp.2018.07.022"xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/author | "Lai X."xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/author | "Li Y."xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/author | "Zhang L."xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/author | "Xiang Y."xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/author | "Zou L."xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/date | "2018"xsd:gYear |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/name | "Int Immunopharmacol"xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/pages | "311-316"xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/title | "Elevation of serum CD5L concentration is correlated with disease activity in patients with systemic lupus erythematosus."xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://purl.uniprot.org/core/volume | "63"xsd:string |
| http://purl.uniprot.org/citations/30173083 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/30173083 |
| http://purl.uniprot.org/citations/30173083 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/30173083 |
| http://purl.uniprot.org/uniprot/#_O43866-mappedCitation-30173083 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30173083 |
| http://purl.uniprot.org/uniprot/O43866 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/30173083 |